The invention discloses a quinoxaline keto-amide compound. The structural general formula is represented as follows, wherein R1 represents a methoxy group or hydrogen, and R represents hydrogen or halogen. The invention further discloses a preparation method of the quinoxaline keto-amide compound and an application of the quinoxaline keto-amide compound in preparing anti-tumor angiogenesis drugs. According to the quinoxaline keto-amide compound, by means of activity evaluation of in-vitro cellular levels and organization levels, angiogenesis of new vessels can be effectively inhibited, and a methyl thiazolyl tetrazolium (MTT) experiment proves that obvious cytotoxicity is absent so that the quinoxaline keto-amide compound can be used as a novel anti-tumor angiogenesis inhibitor, wherein anti-angiogenesis activity of three compounds (SLL-4, SLL-7 and SLL-16) is superior to that of pazopanib of a positive control drug, and a further in-vitro screening result can preliminarily show that the three quinoxaline keto-amide compounds can be expected to be candidate drugs. In a word, a quinoxaline ketone framework is promising to be used for designing and synthesizing the novel anti-tumor angiogenesis inhibitor.